Trials / Terminated
TerminatedNCT02623582
CD123 Redirected Autologous T Cells for AML
Pilot Study of RNA-Redirected Autologous T Cells Engineered to Contain Anti-CD123 Linked to TCR and 4-1BB Signaling Domains in Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Status
- Terminated
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- University of Pennsylvania · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART123) in Acute Myeloid Leukemia (AML) subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes | Given IV |
| DRUG | Cyclophosphamide | Given IV |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2016-08-26
- Completion
- 2016-11-18
- First posted
- 2015-12-07
- Last updated
- 2017-10-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02623582. Inclusion in this directory is not an endorsement.